ramelteon has been researched along with Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
Akechi, T; Ariyoshi, K; Furukawa, T; Hashimoto, H; Hatta, K; Hirayama, T; Iwata, Y; Kayano, A; Maeda, M; Masanori, E; Matsuda, Y; Matsuoka, H; Nakahara, R; Ogawa, A; Ogawa, Y; Okita, N; Oyamada, S; Sadahiro, R; Saito, E; Sasaki, C; Sato, T; Sekimoto, A; Shimada, K; Tokoro, A; Uchitomi, Y; Uezono, Y; Yamaguchi, T; Yamamoto, N; Yanai, Y; Yorikane, E | 1 |
1 review(s) available for ramelteon and Neoplasms
Article | Year |
---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
1 trial(s) available for ramelteon and Neoplasms
Article | Year |
---|---|
A multi-centre, double-blind, randomized, placebo-controlled trial to evaluate the effectiveness and safety of ramelteon for the prevention of postoperative delirium in elderly cancer patients: a study protocol for JORTC-PON2/J-SUPPORT2103/NCCH2103.
Topics: Aged; Aryldialkylphosphatase; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Delirium; Double-Blind Method; Emergence Delirium; Humans; Multicenter Studies as Topic; Neoplasms; Quality of Life; Randomized Controlled Trials as Topic | 2023 |